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Abstract
Aims/hypothesis Treatment of vascular complications of diabetes remains inadequate. We reported that muscle pericytes (MPs)
from limb muscles of vascular patients with diabetes mellitus display elevated levels of oxidative stress causing a dysfunctional
phenotype. Here, we investigated whether treatment with dimethyl-2-oxoglutarate (DM-2OG), a tricarboxylic acid cycle metab-
olite with antioxidant properties, can restore a healthy metabolic and functional phenotype.
Methods MPs were isolated from limb muscles of diabetes patients with vascular disease (D-MPs) and from non-diabetic
control participants (ND-MPs). Metabolic status was assessed in untreated and DM-2OG-treated (1 mmol/l) cells using an
extracellular flux analyser and anion-exchange chromatography–mass spectrometry (IC-MS/MS). Redox status was
measured using commercial kits and IC-MS/MS, with antioxidant and metabolic enzyme expression assessed by quanti-
tative RT-PCR and western blotting. Myogenic differentiation and proliferation and pericyte–endothelial interaction were
assessed as functional readouts.
Results D-MPs showed mitochondrial dysfunction, suppressed glycolytic activity and reduced reactive oxygen species-
buffering capacity, but no suppression of antioxidant systems when compared with ND-MP controls. DM-2OG supple-
mentation improved redox balance and mitochondrial function, without affecting glycolysis or antioxidant systems.
Nonetheless, this was not enough for treated D-MPs to regain the level of proliferation and myogenic differentiation of
ND-MPs. Interestingly, DM-2OG exerted a positive effect on pericyte–endothelial cell interaction in the co-culture
angiogenesis assay, independent of the diabetic status.
Conclusions/interpretation These novel findings support the concept of using DM-2OG supplementation to improve pericyte
redox balance and mitochondrial function, while concurrently allowing for enhanced pericyte–endothelial crosstalk. Such effects
may help to prevent or slow down vasculopathy in skeletal muscles of people with diabetes.
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Abbreviations
CLI Critical limb ischaemia
D-MP Muscle pericyte from diabetic participant
DM-2OG Dimethyl-2-oxoglutarate
EC Endothelial cell
ECAR Extracellular acidification rate
EGM2 Endothelial cell growth medium 2
GSH Glutathione
GSSG Glutathione (oxidised)
HIF1α Hypoxia-inducible factor 1 α
HO-1 Haemoxygenase-1
IC-MS/MS Anion-exchange
chromatography–mass-spectrometry
LDHA Lactate dehydrogenase A
MEM Minimum essential media
MP Muscle pericyte
MSC Mesenchymal stromal cell
MyHC Myosin heavy chain
ND-MP Muscle pericyte from non-diabetic participant
NHDF Adult normal human dermal fibroblast
OCR Oxygen consumption rate
8-OHdG 8-Hydroxy-2′-deoxyguanosine
2OG 2-Oxoglutarate
PECAM Platelet endothelial cell adhesion molecule
PFA Paraformaldehyde
PKCβII Protein kinase C, isoform β II
ROS Reactive oxygen species
RT-qPCR Quantitative RT-PCR
TCA Tricarboxylic acid
Introduction
Globally, an estimated 463 million people are currently living
with diabetes mellitus [1], a major risk factor for cardiovascu-
lar disease [2, 3]. This number is projected to rise over the next
decade [1]. Muscle pericytes (MPs) represent an important
angio-myogenic cell type that interact with endothelial cells
(ECs) to support vascular networks and facilitate angiogenesis
[4, 5]. Diabetes-driven disruption in pericyte–EC interaction is
an important cause of vessel instability and ischaemia [6, 7].
The mechanisms involved are not fully understood but alter-
ations in metabolic flexibility and induction of oxidative stress
is thought to play a role [6, 8]. In line with this, we reported a
reduction in number and function of supporting MP-like cells
of diabetes patients presenting with critical limb ischaemia
(CLI) [9]. Furthermore, these diabetic MPs (D-MPs) had
elevated levels of reactive oxygen species (ROS) and exerted
adverse effects on ECs.
Current treatments to reverse diabetic vascular complica-
tions remain sub-optimal, with approaches targeting metabol-
ic and oxidative stress continuing to be actively pursued [8].
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Given that the diabetic metabolic milieu can imprint on vascu-
lar cells, causing long-lasting changes beyond the restoration
of systemic glucose control [10], a therapeutic option that sits
at the metabolic/signalling interface may have significant
impact. Metabolic intermediates of the tricarboxylic acid
(TCA) cycle may represent one such interface. Among these,
2-oxoglutarate (2OG) may be a promising candidate.
In addition to its role in TCA cycle metabolism, 2OG has
been shown to exert a protective effect through its ability to
increase availability and activity of enzymatic and non-
enzymatic antioxidant systems [11–14]. In this capacity,
2OG appears to have beneficial effects in models of ischaemic
and oxidative stress [11, 13, 15–17]. Furthermore, supplemen-
tation with 2OG has been found to extend cellular lifespan by
decreasing mitochondrial oxidative phosphorylation, indicat-
ing a possible beneficial effect on the ageing process [18].
More recently, 2OG has been suggested to improve the func-
tional activity of cardiac mesenchymal stromal cells (MSCs)
isolated from diabetic participants [19]. This effect was medi-
ated, at least in part, through reducing the hyper-methylated
state and improving glucose uptake and mitochondrial func-
tion, suggesting that this metabolite might prove beneficial as
an additional therapy in diabetic individuals with cardiovas-
cular disease. However, whether 2OG can exert beneficial
effects on diabetes-induced pericyte dysfunction has not been
investigated.
Given these perceived beneficial effects, the aim of this
study was to characterise the metabolic and functional chang-
es in pericyte-like cells isolated from diabetic participants
presenting with CLI, and to investigate whether dimethyl-
2OG (DM-2OG), a cell permeable 2OG derivative, could act
as a ‘therapeutic metabolite’ to restore a healthy metabolic and
functional phenotype.
Methods
Cell culture
Human samples were obtained with written informed consent.
Their use conformed to the principles outlined in the
Declaration of Helsinki and approved by the MultiMedica
Research Ethics Committee (protocol #011/2009). MPs were
isolated from: (1) different anatomical locations of the lower
extremities from non-diabetic control participants, referred for
investigations/therapeutic interventions related to leg varicos-
ity; or (2) foot muscle from type 1 and type 2 diabetic partic-
ipants at the occasion of minor amputation for CLI (diagnosed
according to the Trans-Atlantic Inter-Society Consensus
Document on Management of Peripheral Arterial Disease
[TASC] 2007 guidelines). Characteristics of the study popu-
lation can be found in electronic supplementary material
(ESM) Table 1.
MP isolation was performed following a well-established
procedure described previously [9, 20] (see ESM method:
Muscle pericyte isolation). MPs were sub-cultured in α-
minimum essential media (MEM) (20% vol./vol. FBS) and
used for experimentation between passages 2 and 5. For all
experiments, no randomisation protocol was applied and
investigators were not blinded to the group assignment or to
the experimental results.
HUVECs were purchased from Lonza (Slough, UK) and
cultured on 1% gelatine in endothelial cell growth medium 2
(EGM2). Adult normal human dermal fibroblasts (NHDFs)
were purchased from Promocell (Heidelberg, Germany) and
expanded in fibroblast growth medium before being trans-
ferred to EGM2 for experimentation.
PKCβII overexpression
HEK293-T cells expanded in DMEM (10% vol./vol. FBS)
were transfected with a pLVX-puro plasmid (Clontech, UK)
containing the human protein kinase C, isoformβ II (PKCβII)
sequence under the control of a cytomegalovirus (CMV)
promoter. pLVX-puro-GFP was used as a control. Cells were
collected 48 h post transfection and processed for RNA and
protein analysis.
Cell viability
MP viability was assessed using the Promega (Southampton,
UK) LDH-glo Viability assay following the manufacturer’s
instructions (see ESM method: Cell viability).
Functional analysis
Angiogenesis Angiogenesis was assessed using the 3D co-
culture angiogenesis assay as previously described [21, 22].
NHDFs were cultured to confluence in EGM2 in 24-well
plates. MPs and HUVECs (1:4 ratio) were seeded in EGM2
directly on top of the confluent NHDFs (technical duplicate).
MPs were pre-stained with DiI (1,1′-dioctadecyl-3,3,3′,3′-
tetramethylindocarbocyanine perchlorate; 1:200; 20 min).
Following incubation for 7 days (medium and treatment
refreshed every 48 h), cells were fixed using 4% (wt/vol.)
paraformaldehyde (PFA), and vessel structures were viewed
by staining with anti-platelet endothelial cell adhesion mole-
cule (PECAM) antibody (R&D systems BBA7; 1:200).
Images were acquired using a Zeiss Axio Observer.Z1 fluo-
rescence microscope (Carl Zeiss, UK) and analysed manually
using ImageJ (v 1.52) software (https://imagej.nih.gov/ij/
index.html).
Proliferation MPs were seeded in 96-well plates (1000 cells/
well in triplicate) in the absence or presence of 1 mmol/l DM-
2OG (Sigma Aldrich, UK). Proliferation over 72 h was
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quantified using a BrdU incorporation kit (Sigma Aldrich)
following the manufacturer’s instructions. Medium and treat-
ment were refreshed every 24 h. BrdU (10 μmol/l) was added
for the final 24 h (see ESM method: Proliferation).
Myogenic differentiationMPs were seeded in 8-well chamber
slides and cultured at confluence for 7 days to allow cell
fusion and myotube formation. Cells were fixed with 4%
(wt/vol.) PFA and permeabilised with 0.3% (vol./vol.)
Triton X-100.Myogenic differentiation was assessed by prob-
ing cells overnight (4°C) with anti-myosin heavy chain
(MyHC) antibody (R&D Systems MAB4470; clone MF20;
1:200). Nuclei were counter-stained using DAPI. Images were
acquired using a Zeiss Axio Observer.Z1 fluorescence micro-
scope and analysed using ImageJ software.
Permeability Permeability was assessed by measuring the
transfer of FITC-dextran (4 kDa or 70 kDa) through
HUVEC monolayers in transwell tissue culture plates (see
ESM method: Permeability).
RT-qPCR
RNA was extracted using the Qiagen RNeasy Plus Mini Kit
(Qiagen, UK) according to the manufacturer’s instructions.
Complementary DNA was synthesised using SuperScript II
Reverse Transcriptase (ThermoFisher Scientific, UK).
Quantitative RT-PCR (RT-qPCR), using intercalator (SYBR
Premix Ex-Taq; TaKara Bio, France) and TaqMan technolo-
gies, was performed to determine changes in gene expression.
PRKCB (Hs00176998_m1) and TBP (Hs00427620_m1)
TaqMan primer-probes were obtained from ThermoFisher
Scientific and SHC1 (H1_SHC1) was obtained from Sigma
Aldrich. All other primer sequences were designed using
Primer3 version 4.1.0 (http://primer3.ut.ee/) and NCBI
primer-BLAST software (https://www.ncbi.nlm.nih.gov/
tools/primer-blast/) or obtained from published literature
(ESM Table 2). Analysis was performed using the 2−ΔΔCt
method with results normalised to TBP control gene.
Western blotting
Cells were lysed in RIPA buffer supplemented with protease/
phosphatase inhibitor cocktail (Sigma Aldrich). Protein
concentration was determined by bicinchoninic acid (BCA)
Protein Assay (ThermoFisher Scientific). Proteins (25 μg)
were separated by SDS-PAGE (60–90 min; 120 V).
Resolved proteins were transferred to PVDF membranes
(0.22 μm; GE Healthcare, UK) by semi-dry transfer
(90 min; 22 V). Membranes were blocked (5% wt/vol.
skimmed (non-fat) milk; 1 h) and probed with primary anti-
bodies overnight (4°C) (ESMTable 3) followed by incubation
with ECL-HRP-conjugated secondary antibodies (1:10,000;
1 h) (GE Healthcare). Proteins were detected by enhanced
chemiluminescence using Amersham ECL reagent (GE
Healthcare). Band densities were semi-quantified by densi-
tometry using ImageJ and normalised to β-actin loading
control.
Immunocytochemistry
Cells were fixed in 4% (wt/vol.) PFA (10–15 min) and
permeabilised in 0.1% (vol./vol.) Triton X-100 (15 min).
Cells were incubated in blocking buffer (5% vol./vol. FBS
in PBS-Tween20; 45 min) prior to overnight (4°C) incubation
with primary antibody at optimised concentrations (ESM
Table 4). Primary antibodies were detected with Alexa-
Fluor-488, -568 or -647 secondary antibodies (1:400 in
PBS-Tween20) (ThermoFisher Scientific). Samples were
incubated with DAPI (1:1000; 3 min) and images were
collected using a Zeiss Axio Observer.Z1 fluorescence
microscope.
Metabolic analysis
Anion-exchange chromatography–mass-spectrometry
Metabolites were measured using anion-exchange chromatog-
raphy–mass-spectrometry (IC-MS/MS), similar to that
described previously [23]. Compounds were identified with
reference to accurate mass and retention time compared with
authenticated standards run in-house. All data were normal-
ised to total DNA for each sample and expressed as relative
abundance. Absolute abundance of adenine nucleotides (ATP/
AMP/ADP) was calculated with reference to standard curves
(see ESM method: Anion-exchange chromatography Mass-
Spectroscopy).
Seahorse extracellular flux analysis Changes in oxygen
consumption rate (OCR) and extracellular acidification rate
(ECAR) were measured using the Seahorse XFp extracellular
flux analyzer (Agilent, UK). Baseline readings were obtained,
followed by sequential addition of oligomycin (2 μmol/l),
carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone
(FCCP; 2 μmol/l) and rotenone/antimycin-A (0.5 μmol/l
each). Three readings (5 min intervals) were obtained after
each pharmacological agent and values normalised to protein
content (see ESM method: Seahorse extracellular flux
analysis).
Extracellular lactate accumulation Medium lactate was
measured using ABX-Pentra-C200 chemistry analyser
(HORIBA, UK) with results normalised to protein content
(see ESM method: Extracellular lactate accumulation).
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Measurement of H2O2 Cells (1000 cells/well 96-well plate)
were incubated in the presence or absence of DM-2OG for
16 h (in triplicate). Medium H2O2 level was measured using
the Promega ROS-Glo H2O2 Assay following the manufac-
turer’s instructions (see ESMmethod:Measurement of H2O2).
Measurement of GSH/GSSG Cells were incubated for 16 h in
the absence or presence of 1 mmol/l DM-2OG. Glutathione
(GSH) was measured using the Promega GSH/GSSG-Glo
Assay kit following the manufacturer’s instructions. Results
were normalised to protein content and the reduced GSH/
oxidised GSH (GSSG) ratio was calculated as GSH-GSSG/
(GSSG/2) (see ESM method: Measurement of GSH/GSSG).
Mitochondrial assessment
Mitochondrial DNA content Following extraction of DNA
(QIAamp DNA Mini Kit; Qiagen, UK), a measure of mito-
chondrial to genomic DNA was performed by RT-qPCR
using primers directed against mitochondrial-encoded
tRNA-Leu(UUR) and nuclear-encoded B2-microglobulin, as
described by Rooney et al [24].
Mitochondrial visualisation The mitochondrial-specific stain,
MitoTracker Red-CMXRos (ThermoFisher Scientific), was
used to visualise gross mitochondrial morphology by
fluorescence microscopy. Cells were incubated in α-MEM
containing 50 nmol/l MitoTracker Red-CMXRos dye
(30 min). Images were acquired using a Zeiss Axio
Observer.Z1 fluorescence microscope (×40 objective).
Statistical analysis
Data are expressed as means ± SEM from independent exper-
iments performed on cell isolates from separate donors. Data
analysis was performed using GraphPad Prism 6 software.
Student’s t test was employed for establishing significant
differences between two groups. For comparison of three or
more groups, ANOVA was performed followed by an appro-
priate post hoc test. In all cases, p < 0.05 indicated statistical
significance.
Results
Isolated cells display typical pericyte-related markers
MP-like cells isolated from diabetic patients presenting with
CLI (D-MPs), together with non-diabetic control participants
(ND-MPs), were screened for a combination of pericyte-
associated markers. In line with our previous report [9], isolat-
ed cells were confirmed to be positive for platelet-derived
Fig. 1 (a) Representative images of MitoTracker-stained cells showing
that gross mitochondrial morphology is not different between ND- and D-
MPs; scale bar, 20 μm. (b) Basal OCR is not different between untreated
ND- and D-MPs but is significantly reduced in D-MPs supplemented
with DM-2OG (1mmol/l; 16 h). (c) Maximal OCR and (d) spare capacity
OCR are lower in D-MPs with no effect of DM-2OG supplementation.
(e) ATP-coupling efficiency is significantly lower in D-MPs and is
partially improved following DM-2OG supplementation. (f)
Mitochondrial proton leak is significantly higher in D-MPs and is restored
towards the level of ND-MPs following supplementation with DM-2OG.
(g) No change in relative mitochondrial DNA content was observed
between ND- and D-MPs with or without DM-2OG treatment. Data are
means (± SEM) of n = 3–4 for ND-MP and n = 3 for D-MP; *p < 0.05 as
determined by two-way ANOVA followed by Tukey’s post-comparison
test. Numbers above bars in (c, d) indicate p values. FC, fold change
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growth factor receptor β (PDGFRβ), neuron-glial antigen
(NG2) and CD146, and negative for endothelial marker
CD31 (ESM Fig. 1). Expression of these markers did not
differ between ND- and D-MPs (ESM Fig. 2a). Importantly,
viability was similar between ND- and D-MP and was not
affected by 1 mmol/l DM-2OG (ESM Fig. 2b), a concentra-
tion comparable with that of other studies [25–27].
Mitochondrial function in D-MPs is improved by DM-
2OG
Mitochondrial network morphology was similar between ND-
and D-MPs (Fig. 1a), and no significant difference was
observed in basal mitochondrial OCR (Fig. 1b). However,
maximal OCR and spare capacity were reduced in D-MPs
compared with ND-MPs (Fig. 1c, d). OCR coupled to ATP
production was variable in D-MPs but when considered as a
percentage of basal OCR (ATP-coupling efficiency), was
significantly reduced compared with ND-MPs (Fig. 1e).
Furthermore, D-MPs also showed a significant increase in
non-ATP-linked OCR (mitochondrial proton leak) (Fig. 1f).
Following supplementation with DM-2OG (16 h), basal OCR
was reduced in D-MPs while maximal and spare capacity
were largely unaffected. Moreover, the level of proton leak
was significantly reduced back towards that measured in ND-
MPs. These changes were associated with a partial improve-
ment in ATP-coupling efficiency, although ATP, ADP and
AMP levels did not differ between ND- and D-MPs or follow-
ing supplementation with DM-2OG (ESM Fig. 3). In addition,
no effect of DM-2OG treatment was observed in ND-MPs
(Fig. 1). Importantly, mitochondrial DNA content was similar
between all treatment conditions (Fig. 1g), suggesting mito-
chondrial content remained unchanged.
To understand if changes in OCR were linked with alter-
ations in TCA cycle activity, metabolite abundance was
measured by IC-MS/MS. No difference was found in the level
of citrate, succinate, fumarate or malate (Fig. 2). However,
abundance of cis-aconitate and 2OG were significantly
reduced in D-MPs. Following supplementation with exoge-
nous DM-2OG, intracellular abundance of 2OG was signifi-
cantly increased in both ND- and D-MPs, with no change in
any other metabolite.
Altered mitochondrial function is not a consequence
of PKCβII/p66SHC activation
Upregulation of the PKCβII/p66SHC pathway has been report-
ed as a prominent modulator of mitochondrial function and
Fig. 2 ND- and D-MPs have similar levels of citrate (a), succinate (d),
fumarate (e) and malate (f). D-MPs have significantly reduced levels of
endogenous cis-aconitate (b) and 2OG (c) compared with ND-MPs.
Supplementation with exogenous DM-2OG (1 mmol/l; 16 h)
significantly increased the intracellular abundance of 2OG in both
ND- and D-MPs without affecting other TCA cycle intermediates.
Data represent means (± SEM) of n = 5; *p < 0.05, **p < 0.01,
***p < 0.001 as determined by two-way ANOVA followed by
Student’s t test. FC, fold change
2210 Diabetologia (2020) 63:2205–2217
Fig. 4 Relative abundance of some glycolysis intermediates (a–j) is
significantly altered in D-MPs compared with ND-MPs, indicating
reduced glycolytic activity. DM-2OG supplementation (1 mmol/l; 16 h)
significantly reduces the abundance of fructose-6-phosphate (c) and
lactate (j) in ND-MPs but increases pyruvate abundance (i) in D-MPs.
Data represent means (± SEM) of n = 5; *p < 0.05, **p < 0.01,
***p < 0.001 as determined by two-way ANOVA followed by
Student’s t test. FC, fold change; PFK, phosphofructokinase
Fig. 3 (a) ND- and D-MPs have greater levels ofGLUT1 compared with
GLUT4 at the mRNA level. (b) D-MPs have a significantly reduced level
ofGLUT1mRNA expression compared with ND-MPs. Supplementation
with DM-2OG (1 mmol/l; 16 h) significantly increases GLUT1 mRNA
expression in D-MPs with no effect on ND-MPs. (c) LDHA mRNA
expression is not significantly different between ND- and D-MPs with
or without DM-20G supplementation. (d) Representative western blots
showing GLUT1, LDHA andβ-actin loading control (see ESM Fig. 7 for
original unedited blots) and associated densitometry analysis showing
that D-MPs have a significantly reduced expression of GLUT1 and
LDHA protein compared with ND-MPs, with no significant effect of
DM-2OG supplementation. Data are means (± SEM) of n = 3–4;
*p < 0.05, **p < 0.01, ***p < 0.001 as determined by two-way
ANOVA followed byBonferroni’s post-comparison test. FC, fold change
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ROS production [28–30]. However, RT-qPCR and western
blot analysis revealed that MPs did not express PKCβII to
an extent that could be reliably detected (ESM Fig. 4).
Adequate performance of primers and antibody against
human PKCβII was confirmed using an overexpression
system in HEK293-T cells. Furthermore, a significant reduc-
tion in the expression of the PKCβII target, p66SHC, was seen
in D-MPs (ESM Fig. 4). These data suggest that this pathway
is unlikely to be a significant contributing factor to the altered
mitochondrial function observed in the D-MPs.
Impaired glycolysis and metabolic flexibility in D-MPs
is not rescued by DM-2OG
As glycolysis works alongside mitochondria to sustain vascu-
lar cell function [31, 32], and diabetes is known to affect this
reciprocal interaction [33], we next investigated the impact of
diabetes on markers of glycolysis and the effect of DM-2OG
supplementation.
MPs expressed greater levels of the GLUT1 transport-
er compared with GLUT4 (Fig. 3a), and D-MPs had
significantly less GLUT1 compared with ND-MPs at
both mRNA and protein levels (Fig. 3b, d). D-MPs also
had reduced lactate dehydrogenase A (LDHA) protein
expression, but not mRNA, compared with ND-MPs
(Fig. 3c, d). Following supplementation with DM-2OG
(16 h), GLUT1 mRNA was restored in D-MPs, howev-
er, this was not observed at the protein level. Moreover,
no effect of DM-2OG was observed on LDHA expres-
sion in D-MPs or on GLUT1 and LDHA expression in
ND-MPs (Fig. 3b–d). Analysis of glycolytic intermedi-
ates revealed a significant reduction in glucose, fruc-
tose-6-phosphate, fructose-2,6-bisphosphate and lactate
in D-MPs, and an accumulation in glucose 6-phosphate,
further indicating supressed glycolytic activity (Fig. 4).
Following supplementation with DM-2OG, ND-MPs had
reduced abundance of fructose-6-phosphate and lactate,
suggesting elevated 2OG level reduces glycolytic activ-
ity (Fig. 4). In contrast, DM-2OG-treated D-MPs
showed no alteration in metabolite abundance, except
for an elevation in pyruvate, which may be the result
of altered mitochondrial metabolism or change in other
metabolic pathways involving this metabolite.
To understand if glycolytic capacity and metabolic
flexibility were impacted, the ability to upregulate
anaerobic glycolysis was investigated by measuring the
change in lactate release under hypoxia (2% O2).
Compared with ND-MPs, D-MPs had reduced lactate
release under normoxia and hypoxia, despite both
significantly increasing mRNA expression of the
hypoxia-inducible factor 1 α (HIF1α) target, GLUT1
(ESM Fig. 5a–c). Furthermore, while DM-2OG had no
effect on lactate release by D-MPs, it was significantly
reduced in ND-MPs under normoxic and hypoxic condi-
tions (ESM Fig. 5a). However, the degree of upregula-
tion following hypoxia was similar between untreated
and DM-2OG-treated ND-MPs (ESM Fig. 5d). A simi-
lar change was observed when monitoring ECAR, a
surrogate readout of lactate release, following pharma-
cological inhibition (oligomycin; 2 μmol/l) of ATP-
synthase activity (ESM Fig. 5e).
These data suggest that D-MPs have lower glycolytic activ-
ity and reduced metabolic flexibility, with less capacity for
upregulating glycolysis when required. Supplementation with
DM-2OG has little effect on D-MPs but lowers glycolytic
activity in ND-MPs, without affecting their ability to respond
to hypoxia.
DM-2OG has beneficial effects on D-MP redox status
without upregulating antioxidant systems
We previously demonstrated increased ROS burden in D-MPs
[9], and given the changes in metabolic status described
Fig. 5 (a) D-MPs have reduced H2O2 buffering activity compared with
ND-MPs. Supplementation with DM-2OG (1 mmol/l; 16 h) significantly
reduces medium H2O2 level under all experimental conditions. Data
represent mean (± SEM) percentage of H2O2 level from untreated medi-
um control; n = 3; *p < 0.05, **p < 0.01, ***p < 0.001 as determined by
two-way ANOVA followed by Bonferroni’s post-comparison test. (b) D-
MPs have significantly greater levels of 8-OHdG, a marker of oxidative
DNA damage, with levels unaffected by DM-2OG supplementation. (c)
DM-2OG supplementation significantly reduces the relative abundance
of malondialdehyde, a marker of lipid peroxidation, in both ND- and D-
MPs. For (b, c) data represent means (± SEM) of n = 5; *p < 0.05,
**p < 0.01 as determined by two-way ANOVA followed by Student’s t
test. FC, fold change
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above, we further investigated the redox status in D-MPs and
the ability of DM-2OG to restore redox balance.
D-MPs displayed reduced ability to buffer H2O2 within the
culture medium compared with ND-MPs (Fig. 5a) and
contained higher levels of 8-hydroxy-2′-deoxyguanosine (8-
OHdG), a marker of oxidative DNA damage (Fig. 5b). No
difference was seen in the level of malondialdehyde, an indi-
cator of lipid peroxidation (Fig. 5c). Supplementation with
DM-2OG significantly reduced medium H2O2 under all
experimental conditions (Fig. 5a). However, DM-2OG did
not affect 8-OHdG level but significantly reduced
malondialdehyde in both ND- and D-MPs (Fig. 5b, c).
To identify if the effects of DM-2OG were due to upregulat-
ing antioxidant defence, we assessedMP antioxidant status. ND-
and D-MPs had similar amounts of the H2O2-scavenging
enzyme, catalase, at both the mRNA and protein level (Fig.
6a, c). In contrast, D-MPs had a small, but significant, increase
in haemoxygenase-1 (HO-1) protein, a central antioxidant and
cyto-protective enzyme, while mRNA levels remained
unchanged (Fig. 6b, c). Furthermore, mRNA expression of the
catalytic unit of a rate-governing enzyme of glutathione synthe-
sis, glutamate-cysteine ligase (GCLC) (Fig. 6d), together with
total GSH levels, as measured by IC-MS/MS (Fig. 6e) and the
GSH/GSSG-Glo assay (Fig. 6f), were significantly increased in
D-MPs compared with ND-MPs. Despite this upregulation, the
reduced to oxidisedGSH ratio (GSH/GSSG)was not significant-
ly different (Fig. 6g). Importantly, none of these parameters were
significantly altered by DM-2OG, suggesting that the beneficial
effect of DM-2OG on ROS status is unlikely to be due to induc-
ing antioxidant defence systems.
Pericyte–endothelial interaction is enhanced by DM-
2OG
To understand whether the changes in metabolic and redox
homeostasis are associated with altered functional activity,
in vitro assessment of proliferation, myogenic differentiation
and pericyte–endothelial interaction was performed.
D-MPs displayed a significantly reduced rate of prolifera-
tion compared with ND-MPs, and supplementation with DM-
2OG had a significant inhibitory effect on ND- but not D-MPs
(Fig. 7a). Similarly, D-MPs showed less propensity to differ-
entiate down the skeletal myocyte lineage, with no effect of
DM-2OG being observed (Fig. 7b, c).
Given our previous identification of an adverse impact of D-
MPs on HUVEC 2D network formation [9], we further assessed
the impact of MPs on EC angiogenic behaviour in a 3D co-
culture assay. The mean number and diameter of capillary-like
tubes was not significantly different between wells containing
ND- or D-MPs or following supplementation with DM-2OG
Fig. 6 (a) CAT and (b)HMOX1mRNA expression do not differ between
ND- and D-MPs or following supplementation with DM-2OG (1 mmol/l;
16 h). Data represent means (± SEM) from n = 3. (c) Representative
western blot and associated densitometry analysis showing that HO-1
protein, but not catalase, is significantly increased in D-MPs with no
effect of DM-2OG supplementation. Data represent means (± SEM) from
n = 4 for ND-MP and n = 3 for D-MP; *p < 0.05 as determined by two-
way ANOVA followed by Bonferroni’s post-comparison test. See ESM
Fig. 7 for original unedited blots. (d) GCLC mRNA expression is
significantly higher in D-MPs, with no effect of DM-2OG supplementa-
tion. Data represent means (± SEM) from n = 4; *p < 0.05 as determined
by two-way ANOVA followed by Bonferroni’s post-comparison test. (e)
IC-MS/MS (n = 5) and (f) GSH-Glo assay (n = 3) analysis showing that
total GSH is significantly higher in D-MPs, with no effect of DM-2OG
supplementation. (g) The GSH/GSSG ratio (n = 3) is not significantly
different between ND- and D-MPs or following supplementation with
DM-2OG. For (e–g) data represent means (± SEM); *p < 0.05,
**p < 0.01 as determined by two-way ANOVA. FC, fold change
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(Fig. 8a, b). However, although MPs showed evidence of direct
interaction with ECs, the mean distance between the MP and
endothelial network was significantly greater with D-MPs (Fig.
8c, d), indicating reduced interaction/communication. This
distance was significantly reduced in the presence of DM-2OG,
an effect seen with both D- and ND-MPs, suggesting that DM-
2OG can improve pericyte–endothelial interaction/crosstalk.
To assess whether improved interaction influences endo-
thelial barrier properties, the effect of MPs and DM-2OG on
HUVEC permeability was investigated. The presence of MPs
significantly reduced the ability of large molecules
(represented by 70 kDa FITC-dextran) to pass through a
HUVEC monolayer but had no effect on smaller molecules
(represented by 4 kDa FITC-dextran) (ESM Fig. 6).
Moreover, no significant difference was seen between wells
containing ND- or D-MPs, or those containing DM-2OG.
Together these data demonstrate that D-MPs have reduced
proliferation and differentiation capacity and that DM-2OG
supplementation is not able to rescue these deficiencies. D-
MPs do not adversely impact permeability or the angiogenic
behaviour of healthy ECs but do display less interaction with
the endothelial network, a deficit that is significantly improved
by DM-2OG.
Discussion
The aim of the present study was to characterise the metabolic
and functional changes in D-MPs and identify any beneficial
effect of DM-2OG supplementation.
While the presence of D-MPs did not alter EC permeability
or the ability of ECs to undergo tubulogenesis, D-MPs did
demonstrate a reduction in their proliferative behaviour,
reduced propensity to differentiate down the myogenic line-
age, and reduced interaction with ECs. This impairment in
function is not due to any significant change in cell viability,
but instead can be explained, at least in part, through the
observed changes in D-MP metabolic phenotype imparted
by the diabetic milieu and probably compounded by the isch-
aemic environment from which the cells are isolated.
Cells utilise mitochondria alongside glycolysis to facilitate
signalling and anabolic metabolism aimed at driving prolifer-
ation, migration and morphological re-arrangement [31, 32,
34]. We report that D-MPs have significant alterations in both
glycolysis and mitochondrial metabolism that are in line with
the observed decline in cell function. In agreement with earlier
studies [35, 36], MPs predominantly expressed the GLUT1
transporter that, alongside LDHA, was significantly downreg-
ulated in D-MPs. Alongside this, D-MPs displayed reduced
glycolytic activity and a lack of metabolic flexibility.
Furthermore, D-MPs also presented with significant changes
in mitochondrial function. Although mitochondrial network
morphology and basal OCR was not significantly
compromised, D-MPs had reduced maximal and spare OCR
capacities, together with reduced efficiency of oxygen-linked
ATP production. D-MPs also showed an elevation in proton
leak, an additional indicator of oxidative burden [37, 38].
Such blunted metabolic capacity would contribute to the
reduced functional activity of D-MPs. Indeed, the importance
of upregulating these metabolic networks for such behaviour
has been demonstrated in other vascular cells [31, 32, 34].
Although it was not possible to identify a specific inducer of
the mitochondrial dysfunction, it is possible to rule out activation
of PKCβII, as we were unable to detect this protein kinase.
Unlike other cells, the role of the PKCβII/p66SHC pathway in
pericytes is less studied and mainly restricted to the retina
[39–41]. Even when detected, its role in pericyte biology and
diabetes-related dysfunction remains unclear [41, 42].
Alterations in metabolism are often accompanied by changes
in redox status/control that have a profound impact on vascular
function [43]. We have shown that D-MPs have higher levels of
oxidative stress [9], and in the present study, D-MPs displayed a
greater level of oxidative damage, particularly towards DNA,
and reduced capacity to buffer their environment. Importantly,
this reduction in ROS-buffering does not appear to be due to
compromised expression of antioxidant systems.
Fig. 7 (a) D-MPs show significantly reduced proliferation over 72 h
compared with ND-MPs. Supplementation with DM-2OG (1 mmol/l;
72 h) significantly reduces proliferation of ND- but not D-MPs. Data
represent means (± SEM) fold-change in BrdU incorporation from n = 3;
*p < 0.05 as determined by two-way ANOVA followed by Tukey’s post-
comparison test. (b) Analysis and (c) representative immunofluorescence
images (scale bar, 50μm) showing that D-MPs have reduced propensity to
differentiate down the myogenic lineage compared with ND-MPs at
7 days, with no effect of DM-2OG supplementation. Data represent means
(± SEM) percentage of nuclei associated with positive MyHC staining
(green) from n = 2; ***p < 0.001 as determined by two-way ANOVA
followed by Bonferroni’s post-comparison test. FC, fold change
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Given the potential role of 2OG as an antioxidant and signal-
ling molecule [11–14, 44], we explored whether DM-2OG
supplementation could exert a beneficial effect on metabolic
balance to allow for restoration of D-MP function. This is partic-
ularly pertinent as endogenous 2OG abundance was reduced in
D-MPs, suggesting that a lack of this metabolite may be a
compounding factor in the observed functional decline.
Following DM-2OG supplementation, intracellular abun-
dance of 2OG was elevated. However, the lack of an effect on
antioxidant systems contrasts with reports in other cell types
[12, 14]. Instead, it is possible that DM-2OG is acting, at least
in part, as a direct scavenger of H2O2, as indicated by the
reduction in H2O2 levels within the culture medium. Indeed,
by virtue of its structure, direct 2OG interaction and clearance
of H2O2 has previously been identified, presenting a comple-
mentary antioxidant mechanism [25, 45].
Reduction in oxidative stress is also consistent with the reduc-
tion in mitochondrial OCR and improved efficiency of oxygen-
coupled ATP production observed in DM-2OG-treated D-MPs,
as lower OCR and more efficient mitochondria are less likely to
produce excessive ROS [46]. A similar effect on oxygen
utilisation has been reported previously, where interaction
between 2OG and mitochondrial ATP-synthase was described
[18]. In the current study, DM-2OG supplementation also led to
reduced OCR linked to proton leak, indicating reduced oxidative
burden and improved mitochondrial function. The level of
malondialdehyde was also lowered following DM-2OG
supplementation, suggesting a potential protective effect on lipid
peroxidation state, which could also benefit mitochondria. It is
worth noting that apart from the reduction in malondialdehyde
and medium H2O2 level, none of the above effects were evident
in ND-MPs. This was not due to reducedDM-2OG uptake but is
likely to be a consequence of its differential utilisation, with
greater effects being imparted on reducing glucose metabolism.
Although the reduction in glycolysis could be through 2OG
acting as a positive co-factor for prolyl hydroxylase-mediated
degradation of HIF1α, this does not appear to prevent the ability
to respond to hypoxia or upregulate GLUT1 expression (a
HIF1α target) when required.
Given these differential metabolic effects, it is not surpris-
ing that DM-2OG was unable to restore D-MP proliferation
and reduced proliferation of ND-MPs. The effect of 2OG on
cell proliferation is variable within the literature [47–49], and
our results contrast with those reported in cardiac MSCs,
where 2OG was found to have no effect on metabolic or
proliferative activity of non-diabetic MSCs, but rescued
proliferation of diabetic MSCs in association with a rescue
of glucose metabolism and mitochondrial function [19].
Importantly, DM-2OG was able to enhance pericyte–EC
interaction in the angiogenesis assay. Although the mecha-
nism needs identifying through further investigation, it is like-
ly to involve a combination of effects imparted on both MPs
and ECs. Interestingly, while investigating 2OG for
preventing tumour progression in mice, greater pericyte
Fig. 8 No significant difference
was observed between wells
containing ND- or D-MPs with
regard to the mean number of
branches (a) or mean branch
diameter (b) formed by HUVECs
in the 3D angiogenesis assay. (c)
Quantification and (d)
representative
immunofluorescence images
(scale bar, 50 μm) showing that
the mean distance between
pericytes (red; DiI) and HUVEC
branches (green; PECAM) is
significantly greater in wells
containing D-MPs compared with
ND-MPs and is significantly
reduced when supplemented with
DM-2OG (1 mmol/l; 7 days).
Data represent means (± SEM)
from n = 3; *p < 0.05, **p < 0.01
as determined by two-way
ANOVA followed by
Bonferroni’s post-comparison test
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coverage of vessels was observed following 2OG treatment
[50]. When coupled with our own observation, this may indi-
cate a potential role for 2OG in facilitating pericyte–
endothelial interaction and vessel stability, raising the possi-
bility of utilising 2OG to prevent, or at least slow the rate of,
vascular decline in individuals with diabetes.
These novel findings expand our understanding of themeta-
bolic and behavioural dysfunction that occurs in the MPs of
people with diabetes. Furthermore, these data support the
concept of using DM-2OG as a means of improving pericyte
redox balance and mitochondrial function, while simulta-
neously allowing for enhanced pericyte–endothelial interac-
tion. Given the relatively low sample size assessed in this
study, if these effects are shown to be representative of people
with diabetes then the potential of DM-2OG to slow the rate of
vascular decline in vivo warrants further investigation.
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